Abstract
We examined the potential anxiolytic-like activity of (-)-N-phenyl-7-(hydroxyimino) cyclopropa[b]chromen-1a-carboxamide (PHCCC), an allosteric modulator of metabotropic glutamate4 receptors (mGlu4), after administration into the basolateral amygdala, using the conflict drinking Vogel test in rats as a model. The results indicate that PHCCC, but not 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylate ethyl ester (CPCCOEt), the selective antagonist of group mGlu1 receptors, showed significant, dose-dependent anticonflict effects without affecting the threshold current or water intake. The results indicate that positive allosteric modulation of mGlu4 receptors may be a useful therapeutic approach to anxiety.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alcohol Drinking
-
Allosteric Regulation
-
Amygdala / drug effects
-
Analysis of Variance
-
Animals
-
Anti-Anxiety Agents / pharmacology*
-
Anxiety / prevention & control
-
Behavior, Animal / drug effects
-
Benzopyrans / pharmacology*
-
Chromones / pharmacology
-
Conflict, Psychological
-
Dose-Response Relationship, Drug
-
Drinking Behavior / drug effects
-
Electroshock
-
Male
-
Rats
-
Rats, Wistar
-
Receptors, Metabotropic Glutamate / antagonists & inhibitors
-
Receptors, Metabotropic Glutamate / chemistry
-
Receptors, Metabotropic Glutamate / metabolism*
Substances
-
7-(hydroxyimino)cyclopropan(b)chromen-1a-carbxoylic acid ethyl ester
-
Anti-Anxiety Agents
-
Benzopyrans
-
Chromones
-
N-phenyl-7-(hydroxyimino)cyclopropa(b)chromen-1a-carboxamide
-
Receptors, Metabotropic Glutamate
-
metabotropic glutamate receptor type 1
-
metabotropic glutamate receptor 4